Active not recruitingOBSERVATIONAL

Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada

This study uses information from existing patient medical records, not new treatments, to learn more about how immunotherapy is used for a type of lung cancer called non-small cell lung cancer (NSCLC) in Europe and Canada. Specifically, it's focusing on people who have had surgery for their lung cancer. Researchers are looking at details like who these patients are, what treatments they received before or after their surgery, and how well they did over time, such as their survival rates. The aim is to get a clearer picture of how these real-world treatments are working for patients, without asking anyone to try new medicines or change their care.

At a glance

Status

Active not recruiting

Sponsor

Bristol-Myers Squibb

Enrolment target

300

Start

28 Feb 2026

Estimated completion

31 Mar 2027

Non-Small Cell Lung Cancer

What is this study about?

This study is called 'Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada'. That's a bit of a mouthful, so let's break it down.

At its heart, this study is about understanding how a treatment called immunotherapy is being used in people with a specific type of lung cancer, non-small cell lung cancer (NSCLC), who have had surgery. Researchers in Europe and Canada are looking back at existing medical information, meaning they are reviewing patient records that have already been collected. They aren't asking anyone to take new medicines or attend extra appointments; they're simply analysing information that's already there to learn from it.

The main goal is to see who is getting immunotherapy alongside their surgery, what kind of immunotherapy they're receiving (like nivolumab, pembrolizumab, or durvalumab), and how these treatments affect patient outcomes, such as how long people live after their treatment. By carefully looking at these records, the researchers hope to get a clearer picture of how treatment is working in the 'real world' outside of highly controlled clinical trials. This kind of information can be very valuable for doctors when deciding the best ways to treat future patients.

Key takeaways

This study reviews existing medical records, not new treatments.
It focuses on non-small cell lung cancer patients who had surgery and immunotherapy.
The aim is to understand how immunotherapy is used and its outcomes in Europe and Canada.
No new patient participation is needed; past data is analysed.
The findings will help improve future patient care for lung cancer.
Patient privacy is strictly protected.

Who may be eligible?

To be included in this study, you would need to be an adult (age 18 or older) who was diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC). Your cancer must have been at a specific stage, typically from stage IIA up to stage IIIB, and considered suitable for surgery by your medical team.

Crucially, you must have received a specific type of cancer treatment called immunotherapy (like nivolumab) before your surgery. This study is specifically looking at patients who had this combination of immunotherapy followed by an operation to remove the cancer, so records of both these treatments must be available.

You would not be included in this study if you had been diagnosed with another primary cancer (a new, separate cancer) in the five years leading up to your lung cancer diagnosis, or at any point afterwards. Simple skin cancers (non-melanoma skin cancer) would not count as an exclusion however.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Were you diagnosed with non-small cell lung cancer (NSCLC)?
Was your NSCLC considered suitable for surgery?
Did you receive immunotherapy (like nivolumab) before your lung cancer surgery?
Have you not had a diagnosis of another primary cancer (excluding simple skin cancer) in the last 5 years or since your lung cancer diagnosis?

Answer every question to see your result.

What does participation involve?

This study involves looking at existing medical records only. If your information is used, you wouldn't need to do anything extra. There are no visits, no new tests, no medication to take, and no follow-up appointments connected to this study. Your medical records would simply be reviewed by the research team to gather information about your diagnosis, treatment, and how you responded, as part of a larger group of patients. You wouldn't even know your data was being included, unless you specifically asked your care team about it, as patient privacy is strictly protected.

Potential risks and benefits

Since this study only involves reviewing existing medical records, there are no direct physical risks or benefits to individuals whose records are included. Participants don't receive new treatments or undergo any procedures. The main benefit is to all future patients with non-small cell lung cancer – by analysing this data, doctors can learn more about how different immunotherapy treatments work in real-world settings alongside surgery. This knowledge can help improve future care and guide treatment decisions for others. Your privacy is paramount, and all personal information would be kept strictly confidential, usually by removing any identifying details from the data. You always have the right to discuss your medical information being used for research with your doctor.

Locations (1)

IQVIA
Verified postcode
London, United Kingdom

Common questions

What kind of lung cancer is this study about?

This study is about non-small cell lung cancer (NSCLC), which is the most common type of lung cancer.

Does this study involve trying new medicines?

No, this study only looks at information from existing medical records. Nobody will be asked to try new medicines or change their treatment.

What is immunotherapy?

Immunotherapy is a type of cancer treatment that helps your body's own immune system fight cancer cells.

Will I know if my medical records are part of this study?

Because this study uses existing, anonymised records, you generally wouldn't be individually notified or asked to consent. Your data would be protected to ensure your privacy.

Why is this study important?

It helps doctors understand how different immunotherapy treatments work with surgery for lung cancer in real patients, which can improve care for others in the future.